ERBB2 and neoplasm: In a human epidermal growth factor receptor 2 (HER2 positive) breast cancer mouse model, inhibition of PFKFB3 reduced glucose uptake as well as tumor growth [4], making it a promising treatment target in HER2 positive breast cancer.